BALTIMORE — Real-time continuous glucose monitoring (RT-CGM) is cost-effective in diabetes patients, according to a military study.
In making that determination, a study team led by Walter Reed National Military Medical Center researchers used evidence from a randomized, controlled trial that demonstrated RT-CGM reduced A1C for up to nine months among patients with type 2 diabetes not on prandial insulin.
The study, published recently in the Journal of Diabetes Science and Technology, noted that RT-CGM was offered short-term and intermittently as a self-care tool to affect patients’ behavior.1
Study authors pointed out that the analyses projected lifetime clinical and economic outcomes for RT-CGM vs. self-monitoring of blood glucose by finger-stick only. The base-case analysis was consistent with the randomized control trial — RT-CGM for two weeks on/one week off over three months.
A scenario analysis was used to simulate outcomes of an RT-CGM “refresher” after the active intervention of the trial. Using the IMS CORE Diabetes Model, the analysis was conducted from a U.S. third-party payer perspective, including direct costs obtained from published sources and inflated to 2011 dollars. Costs and health outcomes were discounted at 3% per annum.
Results indicate that life expectancy (LE) and quality-adjusted life expectancy (QALE) from RT-CGM were 0.10 and 0.07, with a cost of $653/patient over a lifetime. In addition, incremental LE and QALE from a “refresher” were 0.14 and 0.10, with a cost of $1,312/patient over a lifetime, while incremental cost-effectiveness ratios were $9,319 and $13,030 per LY and QALY gained.
“RT-CGM, as a self-care tool, is a cost-effective disease management option in the United States for people with type 2 diabetes not on prandial insulin,” study authors concluded. “Repeated use of RT-CGM may result in additional cost-effectiveness.”
1 Fonda SJ, Graham C, Munakata J, Powers JM, Price D, Vigersky RA. The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes. J Diabetes Sci Technol. 2016 Feb 3. pii: 1932296816628547. [Epub ahead of print] PubMed PMID: 26843480.
Other Important VA Studies at the American Diabetes Association 79th Scientific Sessions MIAMI—The first-line drug of choice for Type 2 diabetes, metformin has long been known to effectively reduce blood glucose levels and substantially cut... View Article
SEATTLE—It’s a big job to ensure that VA’s healthcare system is equipped to provide the best possible care to veterans. It might be an even bigger job to make sure that veterans across the country... View Article